Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof

摘要: Combined use of a heparin cofactor II agonist and platelet GPIIb/IIIa receptor antagonist to inhibit both aggregation thrombin generation resulting from disease, injury or responses wound repairs. The combined the can achieve these therapeutic benefits while at same time minimizing reducing risk hemorrhagic side effects (e.g., prolonged bleeding), without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts can, in combination, be therapeutically effective inhibiting generation.